Back to discover

Protein / target

Neutrophil gelatinase-associated lipocalin

Encoded byLCN2P80188Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
2
Research papers

Protein at a glance

Biological role

Iron ion sequestering

Strongest disease association

Psoriasis

Via encoding gene LCN2 · Literature evidence · score 0.12

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development.

View complete UniProt function annotation

Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development (PubMed:12453413, PubMed:20581821, PubMed:27780864). Binds iron through association with 2,3-dihydroxybenzoic acid (2,3-DHBA), a siderophore that shares structural similarities with bacterial enterobactin, and delivers or removes iron from the cell, depending on the context. Iron-bound form (holo-24p3) is internalized following binding to the SLC22A17 (24p3R) receptor, leading to release of iron and subsequent increase of intracellular iron concentration. In contrast, association of the iron-free form (apo-24p3) with the SLC22A17 (24p3R) receptor is followed by association with an intracellular siderophore, iron chelation and iron transfer to the extracellular medium, thereby reducing intracellular iron concentration. Involved in apoptosis due to interleukin-3 (IL3) deprivation: iron-loaded form increases intracellular iron concentration without promoting apoptosis, while iron-free form decreases intracellular iron levels, inducing expression of the proapoptotic protein BCL2L11/BIM, resulting in apoptosis (By similarity). Involved in innate immunity; limits bacterial proliferation by sequestering iron bound to microbial siderophores, such as enterobactin (PubMed:27780864). Can also bind siderophores from M.tuberculosis (PubMed:15642259, PubMed:21978368)

Subcellular location

SecretedCytoplasmic granule lumenCytoplasmic vesicle lumen
Domains and Gene Ontology detail (44)

Gene Ontology

  • Cendoplasmic reticulum
  • Cextracellular exosome
  • Cextracellular region
  • Cextracellular space
  • Cspecific granule lumen
  • Fenterobactin binding
  • Fidentical protein binding
  • Firon ion binding
  • Firon ion sequestering activity
  • Fprotease binding
  • Pacute-phase response
  • Papoptotic process

198 aa · 23 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOImmune signallingUniProt · GOApoptosis & cell deathGO
View supporting evidence

Cell migration

  • ·positive regulation of endothelial cell migration

Immune signalling

  • ·Iron-trafficking protein involved in multiple processes such as apoptosis, innate immuni…
  • ·cellular response to interleukin-1
  • ·cellular response to interleukin-6
  • ·innate immune response

Apoptosis & cell death

  • ·apoptotic process
  • ·negative regulation of hippocampal neuron apoptotic process
  • ·positive regulation of hippocampal neuron apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene LCN2

Gene-level evidence surfaced through the gene LCN2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Obesity due to melanocortin 4 receptor deficiency
0.28Preliminary

Animal model evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Anemia
0.24Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Coronary Artery Disease
0.23Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Psoriasis
0.21Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Acute Kidney Injury
0.15Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

View evidence synthesis (5)
Obesity due to melanocortin 4 receptor deficiencyPreliminary
0.28
agreement 0.100.46
Animal model56%Literature44%

Open Targets aggregate 0.12 · 2 independent evidence families · no direct causal or clinical evidence

AnemiaPreliminary
0.24
agreement 0.070.42
Literature51%Animal model49%

Open Targets aggregate 0.12 · 2 independent evidence families · no direct causal or clinical evidence

Coronary Artery DiseasePreliminary
0.23
agreement 0.050.41
Literature57%Animal model43%

Open Targets aggregate 0.12 · 2 independent evidence families · no direct causal or clinical evidence

PsoriasisPreliminary
0.21
agreement 0.020.40
Literature62%RNA expression38%

Open Targets aggregate 0.12 · 2 independent evidence families · no direct causal or clinical evidence

Acute Kidney InjuryPreliminary
0.15
agreement 0.000.42
Literature100%

Open Targets aggregate 0.12 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Psoriasis0.12
Acute Kidney Injury0.12
Coronary Artery Disease0.12
Neoplasms0.12
Obesity due to melanocortin 4 receptor deficiency0.12
Kidney Failure, Chronic0.12
Breast Neoplasms0.12
Anemia0.12

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality pocket) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandSM · High-Quality PocketAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.